HIV Infections Clinical Trials in Washington D.C., District of Columbia

4 studies are recruiting for hiv infections in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

   This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).

   Stage

   Phase 3

   Ages

   12 and older

   Site

   GSK Investigational Site, Washington D.C., District of Columbia

   Locations

   88 in total

   Run by

   ViiV Healthcare

   See if you can join NCT07650916 on ClinicalTrials.gov

2. Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)

   This randomized Type 1 hybrid effectiveness-implementation trial (N=186) will evaluate the effectiveness and implementation of a peer-delivered problem solving and behavioral activation intervention for adherence to LAI-PrEP/ART ("Peer Activate-LAI") compared to enhanced treatment as usual (ETAU) f…

   Stage

   Not phased

   Ages

   18 to 88

   Site

   HIPS (Harm reduction drop-in center), Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   University of Maryland, Baltimore

   See if you can join NCT06501781 on ClinicalTrials.gov

3. Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

   The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA [Ribonucleic Acid] < 50 [cells per milliliter] c/mL) children 6 to les…

   Stage

   Phase 1

   Ages

   6 to 12

   Site

   GSK Investigational Site, Washington D.C., District of Columbia

   Locations

   8 in total

   Run by

   ViiV Healthcare

   See if you can join NCT05674656 on ClinicalTrials.gov

4. Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

   The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help pre…

   Stage

   Not phased

   Ages

   15 and older

   Site

   Whitman-Walker Health, Washington D.C., District of Columbia

   Locations

   4 in total

   Run by

   Public Health Foundation Enterprises, Inc.

   See if you can join NCT04855773 on ClinicalTrials.gov